ClinicalTrials.gg
TerminatedNCT06293495Updated Sep 25, 2026

Incidence of Cut-out Using Intramedullary Nails With Double Cephalic Screw vs. Unique in Pertrochanteric Fractures

An interventional study of Gamma 3 Nail (Stryker) and Chimaera Nail (Orthofix) in Proximal Femoral Fractures, sponsored by Puerta de Hierro University Hospital. Terminated at 1 site in Spain. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Puerta de Hierro University Hospital · Not applicable, Interventional, and Treatment

Why this study was terminated
The study was terminated early because of limited clinical use of the intramedullary nail with two cephalic screws, resulting in insufficient participant recruitment.
Updated Sep 25, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to compare outcomes in the treatment of proximal femur fractures. The main question it aims to answer is whether the use of a double cephalic screw prevents nail failure (cut-out).

Participants will be treated using open reduction and internal fixation with a proximal femoral nail. Researchers will compare intramedullary nailing with a single cephalic screw (Gamma nail) and with a double cephalic screw (Chimaera nail) to see the cut-out rate.

Read the detailed description

Randomized, open and prospective clinical trial.

Following the surgical indication for open reduction and internal fixation as treatment for proximal femoral fractures, patients will be randomly assigned (ratio 1:1) to one of the following treatments:

Control group: a Gamma 3 nail (single cephalic screw system) will be used for osteosynthesis of the fracture.

Experimental group: a Chimaera nail (system with double cephalic screw) will be used for osteosynthesis of the fracture.

Patient (or their legal guardian) must provide/sign the informed consent prior to inclusion in the study.

After the surgery, patients will be followed-up at 6 weeks, 3 and 6 months. At those times, data related to the radiological examination, the appearance of complications and the walking ability evaluation scale (FAC) will be collected.

02

Conditions studied

  • Proximal Femoral Fractures

Keywords

  • Proximal femoral fracture
  • Hip fracture
  • Cut-out
03

In context

Proximal Femoral Fractures

36 studies on the registry are indexed under Proximal Femoral Fractures; 6 are open to participants now.

This study's enrollment of 200 is above the median of 68 across 22 interventional studies indexed under Proximal Femoral Fractures.

Browse Proximal Femoral Fractures studies →

Lead sponsor

Puerta de Hierro University Hospital is the lead sponsor of 48 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with proximal femur fracture (OTA/AO 31-A1, A2 and A3) requiring surgical treatment.
  • Signing of written according to current legislation before collecting any information, either by the patient or by the legal representative or by people linked by family ties.

Exclusion criteria

Exclusion Criteria:

  • Presence of other fractures in the ipsilateral femur that condition the surgical treatment of the pertrochanteric femur fracture.
  • Subcapital fracture of the proximal femur.
  • Subtrochanteric fracture of the proximal femur.
  • Pathological fracture.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Active comparator
    Single Cephalic Screw System

    A Gamma 3 nail (single cephalic screw system) will be used for osteosynthesis of the fracture.

    Device: Gamma 3 Nail (Stryker)

  • Experimental
    Double Cephalic Screw System

    A Chimaera nail (system with double cephalic screw) will be used for osteosynthesis of the fracture.

    Device: Chimaera Nail (Orthofix)

Interventions

  • DeviceGamma 3 Nail (Stryker)

    Open reduction an internal fixation of proximal femoral fracture with a Gamma 3 nail (single cephalic screw system)

  • DeviceChimaera Nail (Orthofix)

    Open reduction an internal fixation of proximal femoral fracture with a Chimaera nail (system with double cephalic screw)

06

What researchers measure

Primary outcomes

  1. Incidence of cut-out.

    Cut-out is a mechanical complication consisting of varus collapse and migration of the cephalic screw through the femoral head.

    Time frame: 0-6 months

Secondary outcomes

  1. Functional Ambulatory Categories (FAC)

    Classifies patients into 6 categories based on their ability and need for assistance with ambulation. Classifies patients into 6 categories based on their ability and need for help with ambulation, where 0 is equivalent to a patient with the impossibility of ambulation and 5 is a patient completely independent for ambulation.

    Time frame: 0-6 months

  2. Tip-apex distance

    Distance from the tip of the screw to the apex of the femoral head in the anteroposterior and axial views.

    Time frame: 3-6 months

  3. Parker index

    Indicates the distance of the screw from the inferior edge of the femoral neck in anteroposterior view or from the posterior edge of the femoral neck in lateral view.

    Time frame: 3-6 months

  4. Baumgaertner reduction quality criteria

    3 groups are established according to the quality of reduction: good, acceptable and bad

    Time frame: 3-6 months

  5. Number of Surgical complications (Intraoperative)

    Intraoperative complications

    Time frame: 0-1 month

  6. Number of Surgical complications (post-operative)

    Postoperative complications

    Time frame: 0-6 months

07

Study locations

1 site
  • Hospital Universitario Puerta de Hierro Majadahonda
    Majadahonda, Madrid 28222, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2024 to primary completion in Jan 2026, 22 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Sep 2025 → Jan 2026 and completion Apr 2026 → Jan 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2024
First posted
Mar 5, 2024
StartActual
Mar 1, 2024
Primary completionActual
Jan 12, 2026was Sep 2025
CompletionActual
Jan 12, 2026was Apr 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Terminated The study was terminated early because of limited clinical use of the intramedullary nail with two cephalic screws, resulting in insufficient participant recruitment.
changed Sep 25, 2026
Primary completion
Sep 30, 2025→Jan 12, 2026 (actual)
Sep 25, 2026
Study completion
Apr 1, 2026→Jan 12, 2026 (actual)
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Not yet recruiting→Terminated
    Why stopped The study was terminated early because of limited clinical use of the intramedullary nail with two cephalic screws, resulting in insufficient participant recruitment.
    Primary completion Sep 30, 2025→Jan 12, 2026 (now actual)
    Study completion Apr 1, 2026→Jan 12, 2026 (now actual)
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06293495
Lead sponsor
Puerta de Hierro University Hospital
Responsible party
Pedro-José Torrijos-Garrido (Principal Investigator, Puerta de Hierro University Hospital) — Principal investigator
First posted
Mar 5, 2024
Start date
Mar 1, 2024
Primary completion
Jan 12, 2026
Completion
Jan 12, 2026
Last update
Sep 25, 2026

Study contacts

Pedro José Torrijos Garrido, MD, PhD
principal investigator · Study Principal Investigator

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion